Get the Stockscreener App
5.94
1,614%
5.5934
After Hours:
6.22
0.28
+4.71%
Curis Inc stock is traded at $5.94, with a volume of 158.72K.
It is up +1,614% in the last 24 hours and up +1,155% over the past month.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
See More
Previous Close:
$0.3466
Open:
$6.53
24h Volume:
158.72K
Relative Volume:
0.06
Market Cap:
$231.53M
Revenue:
$7.06M
Net Income/Loss:
$-21.17M
P/E Ratio:
-4.9753
EPS:
-1.1939
Net Cash Flow:
$-28.95M
1W Performance:
+1,244%
1M Performance:
+1,155%
6M Performance:
+494.00%
1Y Performance:
+228.18%
1-Day Range:
$5.8335
$6.74
1-Week Range:
$0.3405
$6.74
52-Week Range:
$0.1806
$6.74
Curis Inc Stock (CRIS) Company Profile
Name
Curis Inc
Sector
Industry
Phone
617-503-6500
Address
128 SPRING STREET, LEXINGTON, MA
Compare CRIS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
5.94 | 20.35M | 7.06M | -21.17M | -28.95M | -1.1939 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Apr-04-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Jul-29-20 | Initiated | Laidlaw | Buy |
| Jul-17-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Aug-11-15 | Initiated | FBR Capital | Outperform |
| Jan-22-15 | Reiterated | Oppenheimer | Outperform |
| Jan-21-15 | Reiterated | ROTH Capital | Buy |
| May-09-14 | Reiterated | Oppenheimer | Outperform |
| Oct-02-13 | Initiated | Robert W. Baird | Outperform |
| Sep-30-13 | Initiated | Chardan Capital Markets | Buy |
| Nov-14-12 | Initiated | Stifel Nicolaus | Hold |
| Jan-31-12 | Reiterated | Brean Murray | Buy |
| Jan-31-12 | Reiterated | Summer Street Research | Buy |
| Dec-09-11 | Initiated | Oppenheimer | Outperform |
| Oct-06-11 | Initiated | Summer Street Research | Buy |
| Sep-22-11 | Initiated | MLV Capital | Buy |
| Mar-21-11 | Reiterated | Brean Murray | Buy |
| Feb-26-10 | Reiterated | Roth Capital | Buy |
| Jan-07-10 | Initiated | Roth Capital | Buy |
View All
Curis Inc Stock (CRIS) Latest News
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Curis (CRIS) schedules reverse stock split and split-adjusted trading - Stock Titan
Curis Stockholders Approve 1-for-20 Reverse Split - TipRanks
Curis (NASDAQ: CRIS) sets 1-for-20 reverse stock split after holder vote - Stock Titan
CRIS Q1 2026 Earnings: Significant Earnings Miss Amid No Reported RevenueEarnings Call Q&A - dars.gov.et
$Curis (CRIS.US)$ cold blooded 🤣 - Moomoo
Curis opens 11 sites for CLL study, shareholders approve stock split - Investing.com South Africa
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
$Curis (CRIS.US)$ 💎 in the rough - Moomoo
Curis (CRIS) Launches Phase 2 CLL Study and Plans Reverse Stock Split - GuruFocus
Curis announces eleven active clinical sites in TakeAim CLL study - TipRanks
Price to sales forward of Curis, Inc. – NASDAQ:CRIS - TradingView
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split - PR Newswire
Curis, Inc. Actuals & Estimates (MUN:CUS0) - TradingView
Enterprise value to EBIT forward of Curis, Inc. – NASDAQ:CRIS - TradingView
CUS0 Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBIT forward of Curis, Inc. – LS:A3ETJD - TradingView
Curis Shareholders Approve Flexible Reverse Stock Split Authorization - TipRanks
[8-K] CURIS INC Reports Material Event - Stock Titan
Curis (CRIS) EGM 2026 Summary - Quartr
CRIS: Reverse stock split and adjournment proposals were both approved by majority vote - TradingView
Curis Inc Extraordinary Shareholders Meeting Transcript - GuruFocus
Price to earnings forward of Curis, Inc. – NASDAQ:CRIS - TradingView
CRIS Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Curis, Inc. – LS:A3ETJD - TradingView
Enterprise value to revenue forward of Curis, Inc. – NASDAQ:CRIS - TradingView
Curis (CRIS) Stock Faces Mixed Analyst Target Changes Over Execution And Pipeline Risk - Yahoo Finance
Curis Inc. (CRIS) Edges Higher: Testing Key Resistance Amid Speculative TradingBreakout Stock Alerts - dars.gov.et
Curis StockAnalyst focus and biotech sector review - AD HOC NEWS
Curis Inc (CRIS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Curis Inc (CRIS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Curis Inc (CRIS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Curis Inc (CRIS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Curis Inc (CRIS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Curis Inc (CRIS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Curis Inc (CRIS) Institutional Confidence - TradingKey
Curis Inc (CRIS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Curis Inc (CRIS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Curis Inc Stock (US2312691006): Quarterly earnings keep biotech micro-cap in focus - AD HOC NEWS
CRIS Q1 2026 Earnings: Deep EPS Miss Highlights Pre-Revenue Challenges Amid Strategic PivotQuarterly Earnings - newsline.com
Curis stock (US2312691006): Cancer biotech faces Nasdaq compliance deadline after reverse stock spli - AD HOC NEWS
Q1 2026 Curis Inc Earnings Call Transcript - GuruFocus
Curis (NASDAQ: CRIS) plans reverse stock split to address Nasdaq bid price - Stock Titan
Curis (CRIS) Q1 2026 Earnings Call Transcript - The Globe and Mail
CRIS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Curis Inc. (CRIS) Surges 8.33%: Momentum Builds Above Key SupportVolatility Stop - newsline.com
CRIS News | CURIS INC (NASDAQ:CRIS) - ChartMill
CRIS Q1 2026 Earnings: Significant EPS Miss Highlights Ongoing Pre-Revenue ChallengesEarnings Deceleration Risk - The Legal Advocate
CRIS Q1 2026 Earnings: Development-Stage Biotech Posts Wider-than-Expected Loss with No RevenueEPS Surprise History - newsline.com
CRIS Q1 2026 Earnings: Significant EPS Miss as Biotech Advances Pipeline Without RevenueRevenue Per Share - The Legal Advocate
CRISCuris Inc Stock Price and Quote - Finviz
Curis Inc Stock (CRIS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):